Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for May 2009
May 1, 2009
- VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
- Excess Oral Doses of Acurox Tablets are Disliked by Subjects with a History of Opioid Abuse
May 4, 2009
- Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien Study at ARVO 2009 Annual Meeting
- Tranzyme Pharma's Successful Phase 2 Postoperative Ileus Trial Results to be Presented at the American Society of Colon and Rectal Surgeons 2009 Annual Meeting
- Onset Therapeutics Announces Release of Study Results Demonstrating That ANESTAFOAM (Lidocaine 4% Foam) Reduces Pain Associated with Common Dermatologic Procedures
- Rexahn Reports Positive Preliminary Findings in Zoraxel Clinical Trial to Treat Erectile Dysfunction
- SuperGen's MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients
- TransMolecular Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601
- Narcolepsy is an Autoimmune Disorder, Stanford Researcher Says
- Fovea Reports Positive Results with Prednisporin in Persistent Allergic Conjunctivitis
- Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
- Discovery Labs' KL4 Surfactant Shows Physiologic and Survival Benefit in a Preclinical Model for Severe Respiratory Condition -- Acute Lung Injury
- Inspire Announces Poster Presentations at 2009 Association for Research in Vision and Ophthalmology Annual Meeting
- Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
- Pulmo BioTech Inc. Announces Paper to be Presented at Symposium
- Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR Clinical Study
- Rexahn Reports Positive Preliminary Phase IIa Findings in Zoraxel Clinical Trial to Treat Erectile Dysfunction
- Sciele Pharma and Plethora Solutions Announce Encouraging Results from European Phase III Study on PSD502
- First Oral Drug for Uveitis Reduces Both Inflammation and Recurrence Rate in Potentially Blinding Eye Disease, Reports Lux Biosciences
- Positive Results for Ophthotech's Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
- Results Shown in BioCancell Compassionate Use Trial Using BC-819 for Treatment of Renal Cancer
May 5, 2009
- Northlich Wins Eight Healthcare Advertising Awards and Three Aster Awards for Outstanding Marketing Campaigns
- NicOx co-presents four posters on PF-03187207 for glaucoma at ARVO with Pfizer Inc
- New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
- Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
- New Study Shows Women Experience Significantly Less Unscheduled Bleeding With the ORTHO TRI-CYCLEN(R) LO Birth Control Pill Versus Another Pill
May 6, 2009
- Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
- Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
- Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples
- Metabasis Therapeutics Announces Late-Breaking Abstract on MB07803 Trial Results Accepted for Presentation at the American Diabetes Association Meeting
- BioInvent Reports Positive Phase I Results for BI-204, in Development for Prevention of Cardiovascular Conditions Associated with Atherosclerosis
- Creative MediaWorks Goes Platinum!
- Hypertension: Information Technology to Improve Blood Pressure
- Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
- Pharmaceutical Promotion At Its Productivity Frontier
- Lipoxen Positive Ph I EPO Trial Results
- Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO
- SCORR Marketing Named Agency of Record by Skilled Care Pharmacy
- Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting
- Burzynski Research Institute Announces Positive Results of Phase II ANP Clinical Trial
May 7, 2009
- Analyses of phase 3 blood pressure data for N icOx -- naproxcinod presented at ASH
- Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
- Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
- Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
- Alliance Applauds President's Budget Request for FDA
- Results at ASCO Congress 2009 Highlight Merck's Leadership in Personalizing Cancer Care
- ISTA Pharmaceuticals Highlights Bepreve Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
- ADVENTRX Announces Results From ANX-514 Bioequivalence Study
May 8, 2009
- Archimedes Pharma announces ground breaking phase III data showing NasalFent to be superior to the standard of care for breakthrough cancer pain
- New study results further support the evidence that the HPV vaccine Gardasil will provide long-lasting protection
- The four-type HPV vaccine Gardasil demonstrates real life benefits
- Studies of Gardasil, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of Gardasil Presented at International Papillomavirus Conference
- New Data for GlaxoSmithKline’s Vaccine, Cervarix, Presented at IPV Conference
- Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
- New Data Shows Blood Pressure Reduction Therapy with Benicar and Benicar HCT Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
- New Data Shows Azor (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
- Photo: Levemir Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in Titrate Study
- Rapaflo (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
- Juvaris BioTherapeutics' Universal Influenza Vaccine Protects from Lethal H1N1 and H3N2 Challenges in Pre-Clinical Studies
May 11, 2009
- AstraZeneca Announces Top Line Results From Pivotal Phase III Study for Brilinta
- Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS Liberte Stent
May 12, 2009
- Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients
- Angiotech and Boston Scientific welcome journal article noting important differences between drug-eluting stent brands
- Data From Meta-Analysis Show Clinical Pregnancy Rate With Vaginal Progesterone is Comparable With Intramuscular Progesterone When Administered at Optimal Dosing in Infertility Patients
May 13, 2009
- Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for Euflexxa for the Treatment of Osteoarthritis Knee Pain
- ZymoGenetics Reports Encouraging Preliminary Results from Phase 2 Study of IL-21 in Metastatic Melanoma Conducted by NCIC
- AlphaVax Announces Promising Results in Melanoma Studies
- Pfizer to Present New Clinical Data Highlighting Customized Treatment Approaches For Difficult-To-Treat Cancers
May 14, 2009
- Mesoblast Limited (ASX:MSB) Announce Heart Muscle Function Improved Significantly After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure
- STINSON Brand Innovation, Inc. Celebrates 5 Years in Business
- Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
- Synta Announces Elesclomol Phase 3 Melanoma Data to be Featured in Oral Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
- Aradigm Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis at 2009 International Conference of the American Thoracic Society
- Benefits of Catheter Ablation with the NAVISTAR THERMOCOOL Catheter Sustained for One Year in the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation
- Study Shows Chemotherapy Improves Survival Among Older Breast Cancer Patients
- Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa
May 15, 2009
- Antares Pharma and Population Council Announce Preliminary Positive Phase 2 Trial Results
- Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
- Concordia Pharmaceuticals Reports Encouraging Clinical Data in Patients with K-Ras Mutations Treated with First-in-Class Ras Antagonist, Salirasib
- SPRYCEL (Dasatinib) Shows Potential as Treatment for Prostate Cancer
- OSI Pharmaceuticals Provides Update on OSI-906 Data Being Presented on May 30th at the Upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 16, 2009
May 18, 2009
- VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
- APF530 Phase 3 Data for Chemotherapy-Induced Nausea and Vomiting to be Presented at American Society of Clinical Oncology 2009 Annual Meeting
- BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models at Society of Biological Psychiatry 64rd Annual Scientific Convention & Meeting and Provides EAGLE Phase 2b Update
- Can-Fite Announces Positive Results From Its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) With CF101
- Altair Therapeutics Reports Successful Completion of Phase I Study of Inhaled AIR645
- Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology
- Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
- ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting
- Amgen Highlights Data to Be Presented at ASCO
- Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
- Shire Announces Study Results of the Effects of INTUNIV (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
- BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
- EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
- Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
- Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
May 19, 2009
- Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
- Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
- Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
- Santhera's US Phase III IONIA Trial in Friedreich's Ataxia Misses Primary Endpoint
- AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
- ChemoCentryx's Traficet-EN Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
- Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
- Provectus Reports on Presentation of Chemoablation of Metastatic Melanoma from Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology
- Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
- Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
- NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
- Dynavax Announces Data Presentations at American Thoracic Society Medical Conference
- New Data from ENDEAVOR-II Challenges Conventional Wisdom on Drug-Eluting Stents
- In Patients with Heart Attacks, CYPHER Sirolimus-Eluting Coronary Stent Results Sustained out to Four Years Compared to Bare Metal Stents
- Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
- Altair Therapeutics Reports Successful Completion of phase I study of Inhaled AIR645
- ATS bosentan in combination with tadalafil
- Basilea Pharmaceutica Ltd. (CH) - Basilea presents new efficacy data on BAL30072, its novel antibiotic against Gram-negative bacteria
- Bayer Schering Pharma presents positive results of phase II study with Riociguat
- Velcade (Bortezomib) for Injection and Pipeline Data to Be Highlighted at American Society of Clinical Oncology Annual Meeting
- Addition of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms in Patients Who Responded Only Partially to Previous GAD Treatments
- Upcoming BioAlliance Pharma's Presentations at International Conferences on Infectious Diseases and Oncology
- Continued Growth Drives Move at Mc|K Healthcare
- Kamada Presents New Data on its Alpha-1 Antitrypsin at the American Thoracic Society Annual Meeting
- Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
May 20, 2009
- Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
- Blue Spoon Consulting Publishes White Paper: Pharmaceutical Industry Strategy for a Global Economic System
- Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients
- Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
- Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
- Results of Phase III Study on Labopharm's Novel Antidepressant Published in Psychiatry (Edgemont) Journal
- NicOx presents phase 3 quality of life data for naproxcinod at ISPOR
- Nevo Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
May 21, 2009
- Antisoma plc (UK) - Phase II trial of ASA404 published in Lung Cancer
- Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
- TransMolecular Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting
- Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
- Somaxon Pharmaceuticals Presents Analyses of Silenor Clinical Data at the American Psychiatric Association Annual Meeting
- Phase III Data Show Novartis Investigational Bronchodilator QAB149 Significantly Improves Lung Function Over Current Treatments in COPD
- Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
- Abbott's XIENCE V Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
- Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data In Patients With Schizophrenia
- SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS Express2 Stent System
- PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
- Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
May 22, 2009
- Seidler Bernstein Wins Assignment from Microline PENTAX
- New Data Demonstrate Risperdal Consta (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
May 26, 2009
- Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress
- Boceprevir eliminated Hep C virus in unprecedented number of patients
- Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009
- Widely Used Cancer Drug Bevacizumab Associated with Significantly Increased Risk of Gastrointestinal Perforation
- The Quality and Purity of Biosimilar Epoetin Zeta (Retacrit) is Demonstrated Through Comparative Analysis with Epoetin Alfa - Presented at WCN 2009
- Cytheris Announces Publication of Preclinical Study in Nature Medicine Showing Combination of Interleukin-7 with Viral Vaccine Boosts Immunity to Tumors
- MAP Pharmaceuticals Phase 3 Trial of Levadex Migraine Product Candidate Meets All Four Primary Endpoints
- New Study Evaluating the ADHD Medication VYVANSE (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
- Medinox Announces Clinical Results of Naproxen Prodrug
- OSI Pharmaceuticals to Provide a Summary of Data Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
- Scientific Data Relating to Cinryze Presented at 6th Annual C1 Inhibitor Deficiency Workshop
- Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
- TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
- New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
- NanoGuardian Partners with SDI on Closed-Loop Protection
- Two-Year Data Reinforce Effect of Actemra (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
- First in class uveitis therapy -- Ph3 results highlighted at IOIS
- Proscape Technologies Congratulates Connect Tech, a Division of Draftfcb Healthcare, on Becoming a Gold Certified Content Partner
May 27, 2009
- Addex Pharmaceuticals (CH) - Glutamate Receptor "mGluR5" Implicated in GERD
- Nycomed Reports a Solid Start to 2009
- Affymax Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide Regardless of Patient Baseline Renal Function
- Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorders at Upcoming Conference
- Oncothyreon announces closing of $11.1 million registered direct financing
- Tugboat Consulting Group Announces Key Collaborations To Offer Unique Marketing Products
- CombinatoRx Reports Positive Phase 2 Trial Results for CRx-401
- Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
- GTC Biotherapeutics Announces One-for-Ten Reverse Stock Split
- Genta Incorporated Announces Postponement of Special Stockholders Meeting
- Spectrum Pharmaceuticals to Raise $20 Million from Institutional Investors at $5.11 Per Share, the Closing Bid Price on Tuesday, May 26, 2009
- Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting
- Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
- Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
- Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
- Genaera Receives Non-Compliance Notice from Nasdaq
- Sarah Cannon Research Institute to Present Latest Cancer Research Data at National Clinical Oncology Conference
- Metastatic Colon Cancer: In a Randomized Phase II Clinical Study, Antineoplaston Therapy Doubled the 5-Year Survival Rate Following Curative Resection of Hepatic Metastases
May 28, 2009
- SCORR Marketing Wins Nine Awards in National Marketing Competitions
- Tongjitang Chinese Medicines Company to Announce First Quarter 2009 Financial Results on June 3, 2009
- Biofrontera AG (DE) - Biofrontera raised 3 Million Euro in capital round
- GPC Biotech AG (DE) - GPC Biotech Reports Financial Results for First Quarter 2009
- New Study Results Published Compare Abraxane to Taxotere
- Minster Pharmaceuticals Plc Preliminary Results
- AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
- Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
- CuraGen to Present CR011-vcMMAE Data at ASCO
- Peregrine Pharmaceuticals Reports Progress in Cotara Brain Cancer Clinical Program
- EpiCept Announces Presentation of New Crinobulin Data at 2009 American Society of Clinical Oncology Annual Meeting
- GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Society of Clinical Oncology
- GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
- Oculus Innovative Sciences Announces Fiscal Fourth Quarter Financial Results and Corporate Update Release and Conference Call
- Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
- InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
- Dana-Farber Cancer Institute Presents Results of GlycoMimetics' Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting
- BioMS Medical to Present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
- Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
- Valeant Plans Senior Notes Offering
- Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
- Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
- Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
- Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
- MethylGene Reports Favorable Kinase Inhibitor Data at ASCO Meeting
- Talecris data shows that concentrated form of Prolastin is safe and tolerable; potentially cuts infusion times in half for patients with AAT deficiency
May 29, 2009
- Phase 1 Study for Halozyme's Insulin-PH20 Published, Highlights Findings for Faster Acting Insulin Formulations
- Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
- Lipoxen Raises £2.9m, Led by Baxter Plus Director's Dealings
- Valeant Pharmaceuticals International Sr. Unsecured Debt Ratings Assigned; CCR Affirmed; Outlook Positive
- New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
- Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
- Ore Pharmaceuticals Inc. Announces NASDAQ Deficiency Notice
- Gloucester Pharmaceuticals to Present New Data from Two Studies on Romidepsin at ASCO
- Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
- NPS Reports Three Teduglutide Abstracts Accepted for Presentation at Digestive Disease Week Conference
- Change in the Number of Shares in Vitrolife AB (publ)
- Vion Pharmaceuticals to Present Data on Onrigin at the ASCO Annual Meeting
- Biothera Releases Colorectal Cancer Study Results at ASCO
- YM Biosciences Announces Results Of Randomized Nimotuzumab Study To Be Presented In A Poster At ASCO Annual Meeting
- New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes
- Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen®
- Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer
- Pfizer Invites Public to View and Listen to Webcast of June 12 Conference Call with Analysts at EULAR
- AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO
